Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.
- The 5 Shifts That Could Remake Lyophilization By 2040
- Your 7 Decisions To Make Before MES Configuration
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
GUEST COLUMNISTS
-
The 5 Shifts That Could Remake Lyophilization By 2040
Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
-
Your 7 Decisions To Make Before MES Configuration
Don't wait until manufacturing execution system (MES) configuration to answer these 7 questions. Define your manufacturing process before digitizing it.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
BIOSIMILAR WHITE PAPERS
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
-
Ready To Demystify Organoids?7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
Performance Characteristics Of The Mobius® ADC Reactor For Conjugation10/22/2024
Explore results from a series of studies evaluating the mixing performance of an innovative ADC reactor during the conjugation step utilizing a model fluid.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer3/24/2025
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency and innovation in bioprocessing workflows.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Formycon And Biocelys Combine Complementary Development And Manufacturing Expertise In New Biosimilar Project FYB286
- Samsung Bioepis To Present Clinical And Scientific Data For Oncology Biosimilars At ESMO Congress 2026
- Generic Medicines Manufacturers Ramp Up Patch Supply To Meet Demand
- Alvotech And Advanz Pharma Announce First Known Regulatory Submission Worldwide For Proposed Biosimilar To Eylea® 8 Mg
- Formycon And Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
- Xbrane Announces Full Recruitment Of Pivotal Clinical Trial For Xdivane
- Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- And Short-Acting G-CSF Options
NEWSLETTER ARCHIVE
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
- 10.22.26 -- FDA Modernizes Container Closure Guidance: What Is Changing
- 10.21.26 -- A Sustainable Future: Leveraging 3Rs To Innovate And Accelerate In Testing
- 10.20.26 -- Reduce risk. Move Annex 1 forward.
- 10.15.26 -- You Can't CAPA What You Can't Classify